These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 23896558

  • 1. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging.
    Zhou Z, Wagh NK, Ogbomo SM, Shi W, Jia Y, Brusnahan SK, Garrison JC.
    J Nucl Med; 2013 Sep; 54(9):1605-12. PubMed ID: 23896558
    [Abstract] [Full Text] [Related]

  • 2. Development of hypoxia enhanced 111In-labeled Bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer.
    Wagh NK, Zhou Z, Ogbomo SM, Shi W, Brusnahan SK, Garrison JC.
    Bioconjug Chem; 2012 Mar 21; 23(3):527-37. PubMed ID: 22296619
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.
    Garrison JC, Rold TL, Sieckman GL, Naz F, Sublett SV, Figueroa SD, Volkert WA, Hoffman TJ.
    Bioconjug Chem; 2008 Sep 21; 19(9):1803-12. PubMed ID: 18712899
    [Abstract] [Full Text] [Related]

  • 4. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
    Ho CL, Chen LC, Lee WC, Chiu SP, Hsu WC, Wu YH, Yeh CH, Stabin MG, Jan ML, Lin WJ, Lee TW, Chang CH.
    Cancer Biother Radiopharm; 2009 Aug 21; 24(4):435-43. PubMed ID: 19694578
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
    Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, Maecke HR.
    Cancer Res; 2004 Sep 15; 64(18):6707-15. PubMed ID: 15374988
    [Abstract] [Full Text] [Related]

  • 6. Comparative Study of Subcutaneous and Orthotopic Mouse Models of Prostate Cancer: Vascular Perfusion, Vasculature Density, Hypoxic Burden and BB2r-Targeting Efficacy.
    Zhang W, Fan W, Rachagani S, Zhou Z, Lele SM, Batra SK, Garrison JC.
    Sci Rep; 2019 Jul 31; 9(1):11117. PubMed ID: 31366895
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
    Okarvi SM, Al Jammaz I.
    Nucl Med Biol; 2010 Apr 31; 37(3):277-88. PubMed ID: 20346867
    [Abstract] [Full Text] [Related]

  • 8. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
    Mitran B, Varasteh Z, Selvaraju RK, Lindeberg G, Sörensen J, Larhed M, Tolmachev V, Rosenström U, Orlova A.
    Int J Oncol; 2016 May 31; 48(5):2124-34. PubMed ID: 26983776
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
    Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE.
    J Nucl Med; 2011 Mar 31; 52(3):470-7. PubMed ID: 21321264
    [Abstract] [Full Text] [Related]

  • 10. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC, Xing L, Chen X.
    J Nucl Med; 2006 Mar 31; 47(3):492-501. PubMed ID: 16513619
    [Abstract] [Full Text] [Related]

  • 11. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
    Smith CJ, Gali H, Sieckman GL, Hayes DL, Owen NK, Mazuru DG, Volkert WA, Hoffman TJ.
    Nucl Med Biol; 2003 Feb 31; 30(2):101-9. PubMed ID: 12623108
    [Abstract] [Full Text] [Related]

  • 12. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.
    García Garayoa E, Schweinsberg C, Maes V, Rüegg D, Blanc A, Bläuenstein P, Tourwé DA, Beck-Sickinger AG, Schubiger PA.
    Q J Nucl Med Mol Imaging; 2007 Mar 31; 51(1):42-50. PubMed ID: 17372572
    [Abstract] [Full Text] [Related]

  • 13. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
    Lane SR, Nanda P, Rold TL, Sieckman GL, Figueroa SD, Hoffman TJ, Jurisson SS, Smith CJ.
    Nucl Med Biol; 2010 Oct 31; 37(7):751-61. PubMed ID: 20870150
    [Abstract] [Full Text] [Related]

  • 14. Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours.
    Ferro-Flores G, Arteaga de Murphy C, Rodriguez-Cortés J, Pedraza-López M, Ramírez-Iglesias MT.
    Nucl Med Commun; 2006 Apr 31; 27(4):371-6. PubMed ID: 16531924
    [Abstract] [Full Text] [Related]

  • 15. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
    Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Volkert WA, Hoffman TJ.
    Anticancer Res; 2003 Apr 31; 23(1A):63-70. PubMed ID: 12680195
    [Abstract] [Full Text] [Related]

  • 16. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.
    Hoffman TJ, Gali H, Smith CJ, Sieckman GL, Hayes DL, Owen NK, Volkert WA.
    J Nucl Med; 2003 May 31; 44(5):823-31. PubMed ID: 12732685
    [Abstract] [Full Text] [Related]

  • 17. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
    Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X.
    J Nucl Med; 2009 Jul 31; 50(7):1168-77. PubMed ID: 19525469
    [Abstract] [Full Text] [Related]

  • 18. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS.
    J Nucl Med; 2004 Aug 31; 45(8):1390-7. PubMed ID: 15299066
    [Abstract] [Full Text] [Related]

  • 19. Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopropionic acid and X = H2O or P(CH2OH)3.
    Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Kannan R, Volkert WA, Hoffman TJ.
    Cancer Res; 2003 Jul 15; 63(14):4082-8. PubMed ID: 12874010
    [Abstract] [Full Text] [Related]

  • 20. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.
    Honer M, Mu L, Stellfeld T, Graham K, Martic M, Fischer CR, Lehmann L, Schubiger PA, Ametamey SM, Dinkelborg L, Srinivasan A, Borkowski S.
    J Nucl Med; 2011 Feb 15; 52(2):270-8. PubMed ID: 21233180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.